Enlitic’s Ensight Goes Live at RHCNZ, Advancing Radiology Workflow Efficiency in New Zealand

May 11, 2026 21:32 ET  | Source: Enlitic LOVELAND, Colo., May 11, 2026 (GLOBE NEWSWIRE) — Enlitic, a global leader in radiology and imaging data, today announced the successful go-live of its Ensight platform at RHCNZ Medical Imaging Group (RHCNZ), New Zealand’s largest private radiology provider. The deployment marks Enlitic’s first customer in New Zealand and represents […]

First Participant Dosed in AskBio Phase 1/Phase 2 Gene Therapy Trial of AB-1009 for Late-Onset Pompe Disease (LOPD)

May 11, 2026 08:00 ET  | Source: AskBio Inc. (AskBio) Durham, N.C., May 11, 2026 (GLOBE NEWSWIRE) — AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the first participant has been dosed with investigational gene therapy AB-1009 as part of PROGRESS-GT LOPD, a Phase 1/Phase 2 clinical trial in participants with late-onset Pompe disease (LOPD).  LOPD

Dark Horse Consulting Group and KunTuo Announce Memorandum of Understanding Providing Cell and Gene Therapy Developers with an Accelerated Path to Clinical Development in China

May 11, 2026 07:00 ET  | Source: Dark Horse Consulting Group WALNUT CREEK, Calif., May 11, 2026 (GLOBE NEWSWIRE) — Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, and KunTuo Medical Research and Development (Beijing) Co., Ltd. (“KunTuo”), a full-service contract research organization (CRO) dedicated to clinical research services

BASF Agricultural Solutions successfully commissions new fermentation plant for crop protection products in Ludwigshafen

May 11, 2026 05:00 ET  | Source: BASF Agricultural Solutions Ludwigshafen, Germany, May 11, 2026 – BASF Agricultural Solutions has successfully commissioned its BioHub, a new fermentation plant for biological and biotechnology-based crop protection products, at the Ludwigshafen site. With an investment in the high double-digit million-euro range, BASF is strengthening its portfolio of biological innovations. The

Philips shareholders approve all proposals at the AGM 2026

May 08, 2026 09:01 ET  | Source: Royal Philips May 8, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that its shareholders approved all proposals at the Annual General Meeting of Shareholders (AGM) 2026, including: Feike Sijbesma, Chairman of Philips’ Supervisory Board, said: “On behalf of the Supervisory Board

Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease

May 07, 2026 02:14 ET  | Source: Angelini Pharma; Catalyst Pharmaceuticals ROME and CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) — Angelini Pharma S.p.A. (“Angelini Pharma”), an international pharmaceutical company and part of the Angelini Industries Group, and Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with

CARBOGEN AMCIS Shanghai Site achieves successful outcome in Unannounced NMPA GMP Inspection

May 06, 2026 12:04 ET  | Source: CARBOGEN AMCIS INNOVATIONS AG BUBENDORF, Switzerland, May 06, 2026 (GLOBE NEWSWIRE) — CARBOGEN AMCIS, a Switzerland-based pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, today announces its Shanghai facility has successfully completed an unannounced Good Manufacturing Practice (GMP) inspection by China’s National Medical Products Administration (NMPA), with no observations.

Smith+Nephew drives progress in chronic wound care with ALLEVYN™COMPLETE CARE Dressing and RENASYS™ EDGE tNPWT set to launch at EWMA 2026

May 05, 2026 13:00 ET  | Source: Smith & Nephew UK Ltd Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, continues to drive progress in chronic wound management with an industry-leading portfolio set to showcase at the upcoming European Wound Management Association (EWMA) Conference, Bremen between 6-8 May 2026. Demonstrating a long-term commitment to chronic wound management,

SK pharmteco Achieves SBTi Validation for 2040 Net-Zero Science-Based Targets

May 05, 2026 09:03 ET  | Source: SK pharmteco Inc. RANCHO CORDOVA, Calif., May 05, 2026 (GLOBE NEWSWIRE) — SK pharmteco announced today that its greenhouse gas (GHG) emissions reduction targets have been officially validated by the Science Based Targets initiative (SBTi). This approval confirms that SK pharmteco’s sustainability roadmap aligns with the strict 1.5°C pathway required to fight global climate

Ingredion Incorporated Reports First Quarter 2026 Results

May 05, 2026 06:03 ET  | Source: Ingredion Incorporated WESTCHESTER, Ill., May 05, 2026 (GLOBE NEWSWIRE) — Ingredion Incorporated (NYSE: INGR), a leading global provider of ingredient solutions to the food and beverage manufacturing industry, today reported its first quarter 2026 results. “While we expected a challenging first quarter after last year’s strong first quarter, results were

Teva to Present at the BofA Securities Health Care Conference

May 04, 2026 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J., and TEL AVIV, Israel, May 04, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Eric Hughes, Teva’s EVP of Global R&D & Chief Medical Officer, will present at the BofA Securities Health Care Conference on Tuesday, May

Dr. Falk Pharma and Renexxion announce positive results on naronapride in gastroparesis from the global phase 2b MOVE-IT trial

May 04, 2026 08:00 ET  | Source: Dr. Falk Pharma FREIBURG, Germany and ROSCREA, Ireland – May 4, 2026 – Dr. Falk Pharma GmbH (“Dr. Falk Pharma”), a research-based pharmaceutical company specializing in digestive and metabolic medicine, and Renexxion Ireland Limited (“Renexxion”), a clinical-stage biopharmaceutical company, today announced positive results from MOVE-IT (NCT05621811), a global Phase 2b, randomized

EnGeneIC Announces First Patient Dosed in Recurrent Glioblastoma Clinical Trial

April 30, 2026 15:07 ET  | Source: EnGeneIC SYDNEY, May 01, 2026 (GLOBE NEWSWIRE) — EnGeneIC Limited today announced that the first patient has been dosed in its clinical trial evaluating EnGeneIC’s investigational EGFR-targeted EDV™ (EnGeneIC Dream Vector) therapy in patients with recurrent glioblastoma multiforme (GBM), an aggressive and currently incurable form of brain cancer. The trial

Former Stryker Medical Division President Brad Saar Joins Sonablate Board to Support Growth of Non-Invasive Prostate Cancer Treatment

Appointment signals next phase of expansion for HIFU-based prostate care as demand grows for non-invasive, function-preserving treatment options April 30, 2026 09:03 ET  | Source: Sonablate CHARLOTTE, N.C., April 30, 2026 (GLOBE NEWSWIRE) — Sonablate, a medical technology company focused on non-invasive prostate cancer treatment using high-intensity focused ultrasound (HIFU), today announced the appointment of Brad Saar, former president

Scroll to Top